Back to Search
Start Over
Sunitinib for Metastatic Renal Cell Carcinoma: Real-World Data from the STAR-TOR Registry and Detailed Literature Review.
- Source :
-
Urologia internationalis [Urol Int] 2024; Vol. 108 (3), pp. 198-210. Date of Electronic Publication: 2024 Feb 02. - Publication Year :
- 2024
-
Abstract
- Introduction: We evaluated the effectiveness and safety profile of the tyrosine kinase inhibitor sunitinib in patients with advanced or metastatic renal cell carcinoma (a/mRCC) in a real-world setting.<br />Methods: We analyzed data of adult a/mRCC patients treated with sunitinib. Data were derived from the German non-interventional post-approval multicenter STAR-TOR registry (NCT00700258). Progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were evaluated using descriptive statistics and survival analyses for the entire cohort and patient subgroups.<br />Results: A total of 116 study sites recruited 702 patients treated with sunitinib (73.1% male; median age 68.0 years; median Karnofsky index 90%) between November 2010 and May 2020. The most frequent histological subtype was clear cell RCC (81.6%). Sunitinib was administered as first-line treatment in 83.5%, as second line in 11.7%, and as third line or beyond in 4.8% of the patients. Drug-related AEs and serious AEs were reported in 66.3% and 13.9% of the patients, respectively (most common AE: gastrointestinal disorders; 39.7% of all patients).<br />Conclusions: This study adds further real-world evidence of the persisting relevance of sunitinib for patients with a/mRCC who cannot receive or tolerate immune checkpoint inhibitors. The study population includes a high proportion of patients with unfavorable MSKCC poor-risk score, but shows still good PFS and OS results, while the drug demonstrates a favorable safety profile. The STAR-TOR registry is also registered in the database of US library of medicine (NCT00700258).<br /> (© 2024 S. Karger AG, Basel.)
- Subjects :
- Humans
Male
Aged
Female
Middle Aged
Treatment Outcome
Neoplasm Metastasis
Carcinoma, Renal Cell drug therapy
Carcinoma, Renal Cell secondary
Carcinoma, Renal Cell mortality
Sunitinib therapeutic use
Sunitinib adverse effects
Kidney Neoplasms drug therapy
Kidney Neoplasms pathology
Registries
Antineoplastic Agents therapeutic use
Antineoplastic Agents adverse effects
Subjects
Details
- Language :
- English
- ISSN :
- 1423-0399
- Volume :
- 108
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Urologia internationalis
- Publication Type :
- Academic Journal
- Accession number :
- 38310863
- Full Text :
- https://doi.org/10.1159/000536563